Non-Alcoholic Fatty Liver Disease, An Issue of Clinics in Liver Disease, 1st Edition
著者 :
By Paul J. Gaglio, MD, FACP, AGAF, FAASLD
Due to the current obesity epidemic, non-alcoholic fatty liver disease (NAFLD) is prevalent in a significant portion of the United States patient population. It is being increasingly recognized that NAFLD affects both adults and children and can prog
...view more
Due to the current obesity epidemic, non-alcoholic fatty liver disease (NAFLD) is prevalent in a significant portion of the United States patient population. It is being increasingly recognized that NAFLD affects both adults and children and can progress to end stage liver disease with resultant cirrhosis, portal hypertension, and hepatocellular carcinoma. In addition, several extrahepatic conditions may be linked to NAFLD including cardiovascular disease, insulin requiring and type 2 diabetes mellitus, obstructive sleep apnea, colonic adenomas, hyperuricemia, vitamin D deficiency, hyperferritinemia, pancreatic steatosis, hypothyroidism, and polycystic ovarian syndrome. Therapies for NAFLD are evolving rapidly. This issue will analyze patient demographics, risk factors, pathophysiology, patient presentation, and treatments for NAFLD.
Due to the current obesity epidemic, non-alcoholic fatty liver disease (NAFLD) is prevalent in a significant portion of the United States patient population. It is being increasingly recognized that NAFLD affects both adults and children and can progress to end stage liver disease with resultant cirrhosis, portal hypertension, and hepatocellular carcinoma. In addition, several extrahepatic conditions may be linked to NAFLD including cardiovascular disease, insulin requiring and type 2 diabetes mellitus, obstructive sleep apnea, colonic adenomas, hyperuricemia, vitamin D deficiency, hyperferritinemia, pancreatic steatosis, hypothyroidism, and polycystic ovarian syndrome. Therapies for NAFLD are evolving rapidly. This issue will analyze patient demographics, risk factors, pathophysiology, patient presentation, and treatments for NAFLD.
著者情報
By Paul J. Gaglio, MD, FACP, AGAF, FAASLD, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY
https://shop.elsevier.jp/non-alcoholic-fatty-liver-disease-an-issue-of-clinics-in-liver-disease-9780323416979.html302342Non-Alcoholic Fatty Liver Disease, An Issue of Clinics in Liver Diseasehttps://secure-ecsd.elsevier.com/covers/80/Tango2/large/9780323416979.jpg11817.5513903JPYInStock/Medicine & Surgery/Gastroenterology & Hepatology/eBooks/Medicine/Gastroenterology & Hepatology/eBooks/eBooks/Medicine/Gastroenterology & Hepatology/Medicine/Gastroenterology & Hepatology/Product Format/E-Book/Product Format/E-Book/Product Format/E-Book/Product Format/E-Book433513943887245054607505466552550405259894580354159368005936822593682759368321418269243350884886536505455351451205259833579989258035265936799593680959368235936828Due to the current obesity epidemic, non-alcoholic fatty liver disease (NAFLD) is prevalent in a significant portion of the United States patient population. It is being increasingly recognized that NAFLD affects both adults and children and can progress to end stage liver disease with resultant cirrhosis, portal hypertension, and hepatocellular carcinoma. In addition, several extrahepatic conditions may be linked to NAFLD including cardiovascular disease, insulin requiring and type 2 diabetes mellitus, obstructive sleep apnea, colonic adenomas, hyperuricemia, vitamin D deficiency, hyperferritinemia, pancreatic steatosis, hypothyroidism, and polycystic ovarian syndrome. Therapies for NAFLD are evolving rapidly. This issue will analyze patient demographics, risk factors, pathophysiology, patient presentation, and treatments for NAFLD. Due to the current obesity epidemic, non-alcoholic fatty liver disease (NAFLD) is prevalent in a significant portion of the United States patient population. It is being increasingly recognized that NAFLD affects both adults and children and can progress to end stage liver disease with resultant cirrhosis, portal hypertension, and hepatocellular carcinoma. In addition, several extrahepatic conditions may be linked to NAFLD including cardiovascular disease, insulin requiring and type 2 diabetes mellitus, obstructive sleep apnea, colonic adenomas, hyperuricemia, vitamin D deficiency, hyperferritinemia, pancreatic steatosis, hypothyroidism, and polycystic ovarian syndrome. Therapies for NAFLD are evolving rapidly. This issue will analyze patient demographics, risk factors, pathophysiology, patient presentation, and treatments for NAFLD.00add-to-cart97803234169792016専門医By Paul J. Gaglio, MD, FACP, AGAF, FAASLD20161E-BookElsevier02016/08/09IN STOCKBy <STRONG>Paul J. Gaglio</STRONG>, MD, FACP, AGAF, FAASLD, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NYE-BookE-BookThe Clinics: Internal MedicineS013Gastroenterology & Hepatology, Medicine米国いいえいいえいいえいいえいいえ選択してください選択してくださいいいえいいえ選択してください